Sangamo Therapeutics, Inc. (SGMO)
0.4826
-0.02
(-4.11%)
USD |
NASDAQ |
Dec 10, 16:00
0.473
-0.01
(-1.99%)
After-Hours: 06:06
Sangamo Therapeutics Cash from Investing (Quarterly): -0.064M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Novavax, Inc. | -136.53M |
| Arcturus Therapeutics Holdings, Inc. | -0.1949M |
| Pfizer Inc. | -2.43B |
| AIM ImmunoTech, Inc. | 0.296M |
| Protalix Biotherapeutics, Inc. | -0.504M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.50M |
| Cash from Financing (Quarterly) | 19.20M |
| Free Cash Flow | -76.40M |
| Free Cash Flow Per Share (Quarterly) | -0.0939 |
| Free Cash Flow to Equity (Quarterly) | -30.52M |
| Free Cash Flow to Firm (Quarterly) | -28.56M |
| Free Cash Flow Yield | -63.85% |